| Pharmaceutical Information |
| Drug Name |
Aldesleukin |
| Drug ID |
BADD_D00062 |
| Description |
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. |
| Indications and Usage |
For treatment of adults with metastatic renal cell carcinoma. |
| Marketing Status |
approved |
| ATC Code |
L03AC01 |
| DrugBank ID |
DB00041
|
| KEGG ID |
D00748
|
| MeSH ID |
C082598
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D05PUD
|
| NDC Product Code |
76310-022; 17089-380 |
| UNII |
M89N0Q7EQR
|
| Synonyms |
aldesleukin | Proleukin | BAY 50-4798 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
110942-02-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
